To: Doug R who wrote (40232 ) 11/30/2001 10:09:43 PM From: Sergio H Respond to of 79273 Thanks Doug. I appreciate your read on EXAC. Sounds good. I bought this stock looking to hold it for the next year unless the situation changes. I looked at the two stocks you mentioned. CLGY and SIGM are both worth consideration on a fundamental basis on future prospects. Of the two I like CLGY better because I can understand what they do and because I think their sector is more timely. SIGM is cutting edge high tech and will soar if they manage to land a deal with someone like Motorola or Verizon. CLGY is being accumulated by instititutions. They recently were successful in completing a private placement and they have a trio of late stage drugs that will be hitting the market over the next two years. A probable catalyst for CLGY's stock price is likely to be marketing announcements followed by FDA approvals. CLGY's prospects combine well with your bullish technical prediction. The website for one of the analysts offering coverage on CLGY provides more details for anyone interested:unterberg.com Thanks for pointing me to this stock. I like it and bought it. The price movement was very active for such small volume. I think the biotechs and the health care stocks will lead the market for the next year or so. The small caps in these sectors are great buyout candidates while the larger pool stands to benefit from a variety of reasons. It is likely that these sectors are going to receive increased coverage as there has been an increase in biotech/health care analyst hiring, as opposed to staff reductions in other sectors. Rather than putting in my own words, I'll let Gruntal's recent comments paint the picture: <Gruntal & Co., L.L.C. believes that biotechnology and pharmaceutical stocks are well positioned to thrive in the 21st Century. Scientific discoveries have led to many new blockbuster drugs and medical products to better serve the ever-growing and aging population. These breakthroughs have improved the quality of life and life expectancy of millions. Moreover, new technologies, such as generics, are providing avenues of growth never before imagined. Debilitating diseases, previously untreatable, are now often manageable or even curable. The global market for drugs has the potential to see significant growth in the future, up from its present estimated size of $300 billion.* We believe that these dynamic economic,social, and technological changes will propel sales, earnings, and stock valuations higher over time for select companies. Gruntal has created the Biotechnology & Pharmaceutical Growth Trust to give investors the opportunity to take advantage of the potential growth in this exciting sector of the stockmarket. In Gruntal opinion, the best years for the biotechnology and pharmaceutical industries lie ahead. > Sergio